NCT07043972View on ClinicalTrials.gov

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

January 1, 2030

Study Completion Date

January 1, 2031

Conditions
Urothelial Carcinoma
Interventions
DRUG

Gemcitabine

IV over 30 minutes given on days 1 and 8 of a 21 day cycle

DRUG

Carboplatin

IV over 30 minutes given on day 1 of a 21 day cycle

Trial Locations (2)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

19140

RECRUITING

Temple University Hospital at Broad Street, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT07043972 - Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma | Biotech Hunter | Biotech Hunter